FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W334309702> ?p ?o ?g. }

• W334309702 endingPage "2833" @default.
• W334309702 startingPage "2833" @default.
• W334309702 abstract "Abstract Introduction The objective of this study is to evaluate the persistence patterns and discontinuation rates from ruxolitinib in clinical practice. Ruxolitinib was the first Janus kinase (JAK) inhibitor approved for treating intermediate-risk or high-risk myelofibrosis, including primary myelofibrosis, post‒polycythemia vera myelofibrosis, and post‒essential thrombocythemia myelofibrosis. Ruxolitinib was investigated in 2 randomized, controlled, phase 3 efficacy trials in patients diagnosed with myelofibrosis (COMFORT-I and COMFORT-II). Methods A retrospective database inception cohort study is developed from 2 large US claims databases, the IMS Health® database containing National Council for Prescription Drug Programs pharmacy-dispensed prescription claims and the MarketScan® database containing patient-level data from approximately 100 health plans (data from active employees, early retirees, COBRA continues, and dependents) and from Medicare Supplemental data. We identify a cohort of myelofibrosis patients who were prescribed ruxolitinib between November 1, 2011 and August 31, 2012 in the IMS database and between November 1, 2011 and June 30, 2012 from the MarketScan database. Patients are followed from the date of the first ruxolitinib claim, defined as the index date, until the last enrollment date or date of last claim recorded if greater than the last enrollment date in the MarketScan database or for a fixed 3- and 6-month period in the IMS database. When analyzing treatment discontinuation, patients with primary or secondary myelofibrosis are required to have ≥1 ruxolitinib dispensed prescription(s) and to have ≥3 months of pre-index data and ≥3 or 6 months of follow-up post-index data. Discontinuation of ruxolitinib was defined as a >30-day gap from the last day of supply from the prior prescription fill. Demographic and ruxolitinib discontinuation rates at 3 and 6 months post-index date for patients in each database are reported in this analysis with the Clopper-Pearson confidence interval. Results In patients prescribed ruxolitinib in the IMS database, mean (SD) age at the index date was 63.4 (13.2) years for patients followed for 3 months (n=183) and 63.3 (13.6) years for patients followed for 6 months (n=115). The MarketScan database inception cohort comprised 161 patients with mean (SD) age of 66.8 (12.2) years. Age was comparable and not substantially different across the 2 databases. Discontinuation rates in the IMS database were 60.9% and 73.0% at 3 and 6 months follow-up, respectively; in the MarketScan database, discontinuation rates were 41.1% and 48.4% for patients with a minimum of 3 and 6 months follow-up, respectively. Conclusions These analyses indicate that the discontinuation rates for patients receiving treatment with ruxolitinib for myelofibrosis are not low and are most pronounced within the first 3 months of treatment. Results suggest the magnitude of unmet need in myelofibrosis and for additional medications that can improve treatment outcomes. Limitations of this study pertain to a traditional claims database inquiry. As patients were identified from 2 distinct databases, there may be some data overlap. Diagnostic information on the basis of claims databases is not always accurate. Future research using rich clinical data from chart reviews is needed to identify clinical determinants of persistence/discontinuation. The discontinuation rates observed from these 2 large representative databases are substantial, reflecting inherent variability of point estimates and differences in data collection for the 2 data sources. Future studies should examine the reasons for discontinuation so that findings may be incorporated into disease/medication adherence management programs. Disclosures: Fonseca: IMS Health - a company that received funds from Sanofi to conduct the study: Employment. Silver:Sanofi : Consultancy, Research Funding. Kazis:Sanofi and IMS: Consultancy. Iqbal:Sanofi: Employment, Equity Ownership. Rose:Sanofi: Employment. Khan:IMS Health: Employment." @default.
• W334309702 created "2016-06-24" @default.
• W334309702 creator A5016280533 @default.
• W334309702 creator A5026974588 @default.
• W334309702 creator A5040941721 @default.
• W334309702 creator A5062831158 @default.
• W334309702 creator A5069483554 @default.
• W334309702 creator A5070927851 @default.
• W334309702 date "2013-11-15" @default.
• W334309702 modified "2023-10-18" @default.
• W334309702 title "Ruxolitinib Discontinuation In Patients With Myelofibrosis: An Analysis From Clinical Practice" @default.
• W334309702 doi "https://doi.org/10.1182/blood.v122.21.2833.2833" @default.
• W334309702 hasPublicationYear "2013" @default.
• W334309702 type Work @default.
• W334309702 sameAs 334309702 @default.
• W334309702 citedByCount "12" @default.
• W334309702 countsByYear W3343097022014 @default.
• W334309702 countsByYear W3343097022016 @default.
• W334309702 countsByYear W3343097022020 @default.
• W334309702 countsByYear W3343097022021 @default.
• W334309702 countsByYear W3343097022022 @default.
• W334309702 crossrefType "journal-article" @default.
• W334309702 hasAuthorship W334309702A5016280533 @default.
• W334309702 hasAuthorship W334309702A5026974588 @default.
• W334309702 hasAuthorship W334309702A5040941721 @default.
• W334309702 hasAuthorship W334309702A5062831158 @default.
• W334309702 hasAuthorship W334309702A5069483554 @default.
• W334309702 hasAuthorship W334309702A5070927851 @default.
• W334309702 hasConcept C126322002 @default.
• W334309702 hasConcept C187212893 @default.
• W334309702 hasConcept C2426938 @default.
• W334309702 hasConcept C2776112149 @default.
• W334309702 hasConcept C2778715236 @default.
• W334309702 hasConcept C2780007613 @default.
• W334309702 hasConcept C2780076729 @default.
• W334309702 hasConcept C41008148 @default.
• W334309702 hasConcept C71924100 @default.
• W334309702 hasConcept C72563966 @default.
• W334309702 hasConcept C77088390 @default.
• W334309702 hasConcept C98274493 @default.
• W334309702 hasConceptScore W334309702C126322002 @default.
• W334309702 hasConceptScore W334309702C187212893 @default.
• W334309702 hasConceptScore W334309702C2426938 @default.
• W334309702 hasConceptScore W334309702C2776112149 @default.
• W334309702 hasConceptScore W334309702C2778715236 @default.
• W334309702 hasConceptScore W334309702C2780007613 @default.
• W334309702 hasConceptScore W334309702C2780076729 @default.
• W334309702 hasConceptScore W334309702C41008148 @default.
• W334309702 hasConceptScore W334309702C71924100 @default.
• W334309702 hasConceptScore W334309702C72563966 @default.
• W334309702 hasConceptScore W334309702C77088390 @default.
• W334309702 hasConceptScore W334309702C98274493 @default.
• W334309702 hasIssue "21" @default.
• W334309702 hasLocation W3343097021 @default.
• W334309702 hasOpenAccess W334309702 @default.
• W334309702 hasPrimaryLocation W3343097021 @default.
• W334309702 hasRelatedWork W2129148152 @default.
• W334309702 hasRelatedWork W2547101781 @default.
• W334309702 hasRelatedWork W2751586730 @default.
• W334309702 hasRelatedWork W3120572889 @default.
• W334309702 hasRelatedWork W3141140978 @default.
• W334309702 hasRelatedWork W3165639147 @default.
• W334309702 hasRelatedWork W4207016570 @default.
• W334309702 hasRelatedWork W4221100544 @default.
• W334309702 hasRelatedWork W4251586583 @default.
• W334309702 hasRelatedWork W4283399567 @default.
• W334309702 hasVolume "122" @default.
• W334309702 isParatext "false" @default.
• W334309702 isRetracted "false" @default.
• W334309702 magId "334309702" @default.
• W334309702 workType "article" @default.